Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Novo Nordisk maintains the highest strategic value in the GLP-1 Weight Loss Drug Market competitive landscape through first-mover advantage in dedicated obesity pharmacotherapy, manufacturing scale exceeding 24 billion API doses annually following the Catalent site acquisition, and a multi-indication strategy converting Wegovy into a broad metabolic disease platform
)
El programa tambin exige que los proveedores certifiquen que un GLP-1 recetado es para reducir el exceso de peso y mantener la prdida de peso en combinacin con cambios en el estilo de vida, incluyendo dieta y ejercicio, dice CMS
What the future may hold
Generic availability timeline: when patents expire No GLP-1 receptor agonist is currently available as a true generic (an FDA-approved generic with an ANDA filing)
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 22.39
US$ 28.06
US$ 26.55
